Verismo Therapeutics reports early Phase I data on SynKIR-110, a KIR-CAR T cell therapy designed to combat T cell exhaustion in solid tumors with a multi-chain NK-inspired architecture that activates only upon target encounter.

The KIR-CAR platform may offer advantages over traditional single-chain CARs by sustaining activity in challenging tumor microenvironments, as presented by Verismo.

STAR-101 Phase I data from AACR 2026 show SynKIR-110 in advanced mesothelin-expressing solid tumors, including ovarian cancer, mesothelioma, and cholangiocarcinoma.

The trial continues with dose escalation to establish the recommended Phase 2 dose and further assess safety and preliminary efficacy.

Expansion cohorts are ongoing to confirm safety and look for signs of efficacy at the selected dose level.

Enrollment remains active as researchers monitor safety and determine the optimal dose for the next phase.

The press release includes forward-looking language and standard licensing and investor media contact details.

Interim data show a partial response at dose level 3 per RECIST, with the response ongoing beyond three months as of the September 2025 cutoff.

In broader interim results, one patient at the highest dose achieved a partial response, while others showed disease stabilization at dose level 3.

Dr. Janos L. Tanyi of Penn presented the data; Penn IP is licensed to Verismo, highlighting a Penn-originated collaboration.

Nine patients across three dose cohorts demonstrated a favorable safety profile with no dose-limiting toxicities, low-grade CRS in a subset, and no ICANS.